Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis (Aging Clinical and Experimental Research, (2022), 34, 11, (2625-2634), 10.1007/s40520-022-02272-z)

Nicholas Fuggle, Nasser Al-Daghri, Olivier Bock, Jaime Branco, Olivier Bruyère, Enrique Casado, Etienne Cavalier, Bernard Cortet, Maarten de Wit, Andrea Giusti, Philippe Halbout, Nicholas C. Harvey, Mickaël Hiligsmann, Jean Marc Kaufman, Andreas Kurth, Stefania Maggi, Radmila Matijevic, Salvatore Minisola, Santiago Palacios, Régis Pierre RadermeckerFriederike Thomasius, Sansin Tuzun, Nicola Veronese, John A. Kanis, Jean Yves Reginster, René Rizzoli, Cyrus Cooper

Research output: Contribution to journalComment/debatepeer-review

17 Downloads (Pure)

Abstract

In the published article, the author would like to update the following lines from Gastrointestinal adverse events were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal. to History of Gastrointestinal symptoms were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal in the published article. The original article has been updated.

Original languageEnglish
Pages (from-to)1375 - 1376
JournalAging Clinical and Experimental Research
Volume35
Issue number6
Early online date2023
DOIs
Publication statusPublished - Jun 2023

Fingerprint

Dive into the research topics of 'Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis (Aging Clinical and Experimental Research, (2022), 34, 11, (2625-2634), 10.1007/s40520-022-02272-z)'. Together they form a unique fingerprint.

Cite this